Safety Study of a Bioresorbable Coronary Stent

Inclusion Criteria: * Evidence of myocardial ischemia or a positive functional study. * Normal CK-MB. * Target lesion must be located in a native coronary artery where target vessel diameter is ≥ 2.9 mm and ≤ 3.3 mm and target lesion length is ≤ 12 mm, both assessed by on-line QCA and IVUS * Target lesion must be in a major artery or branch with a visually estimated stenosis of ≥ 50% and \< 100% with a TIMI flow of ≥ 2. * Staged procedures are allowed in non-target vessels \>24 hours before or \> 30 days after REVA stent implantation Exclusion Criteria: * A myocardial infarction (CK-MB or Troponin \> 3 times normal) within 72 hours of the procedure, has signs or symptoms of an ongoing myocardial infarction or has any visible thrombus * Unprotected left main coronary disease with \>50% stenosis * The target vessel is totally occluded (TIMI Flow 0 to 1) * Target lesion involves a bifurcation (a lesion with a side branch \>2.0 mm in diameter containing a \>50% stenosis) * Target lesion is located within a segment supplied by distal graft * Target lesion has possible or definite thrombus